Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer

Tvrdík,D.; Staněk,L.; Skálová,H.; Dundr,P.; Velenská,Z.; Povýšil,C.

doi:10.3892/mmr.2012.919

Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer

Authors:
- D. Tvrdík
- L. Staněk
- H. Skálová
- P. Dundr
- Z. Velenská
- C. Povýšil
View Affiliations

Affiliations: Institute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, 12800 Prague 2, Czech Republic
Published online on: May 17, 2012 https://doi.org/10.3892/mmr.2012.919
Pages: 439-443

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Her2 proto-oncogene amplification and protein overexpression is observed in 20-40% of patients with breast cancer and plays a crucial role in invasive breast cancer and its treatment. In the present study, we investigated samples from 131 patients with invasive breast carcinoma. In all cases, the overexpression/amplification level of Her2 was determined using manual immunohistochemistry (IHC) and/or automatic IHC, fluorescence in situ hybridization (FISH), silver in situ hybridization (SISH) and quantitative polymerase chain reaction (qPCR). Using various methods, we demonstrated candidate methods for Her2 detection and their dependability. Our results demonstrate that these methods are highly comparable for the detection of Her2 overexpression/amplification. It was also revealed that qPCR is a valuable tool for the evaluation of Her2 gene overexpression/amplification. The results from pPCR analysis positively correlated with the results from IHC and FISH analysis. Moreover, in contrast to IHC or SISH/FISH, the results obtained by qPCR were not encumbered with any subjective error on the part of the evaluator.

View Figures

View References

1	Slamon DJ, Godolphin W, Jones LA, et al: Studies of Her2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989.
2	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987.
3	Andrulis IL, Bull SB, Blackstein ME, et al: Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 16:1340–1349. 1998.
4	Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 15:2894–2904. 1997.
5	Ro JS, El-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H and Hortobagyi G: C-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 49:6941–6944. 1989.
6	Paterson MC, Dietrich KD, Danyluk J, et al: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 51:556–567. 1991.
7	Duffy MJ: Predictive markers in breast and other cancers: a review. Clin Chem. 51:494–503. 2005.
8	Davoli A, Hocevar BA and Brown TL: Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol. 65:611–623. 2010.
9	Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M and Steinhoff MM: Her2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy. Breast Cancer. 12:294–298. 2005.
10	Jones C, Ford E, Gillett C, et al: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res. 10:5988–5997. 2004.
11	Van de Vijver M: Gene-Expression profiling and the future of adjuvant therapy. Oncologist. 10:30–34. 2005.
12	Hoff ER, Tubb RR, Myles JL and Procop GW: Her2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 117:916–921. 2002.
13	Skálová H, Dundr P, Povýšil C, Velenská Z, Petruželka L and Tvrdík D: Study of the effect of neoadjuvant chemotherapy on the status of Her2/neu. Folia Biol (Praha). 57:191–199. 2011.
14	Biéche I, Onody P, Laurendeau I, Martine O, Vidaud D, Lidereau R and Vidaud M: Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 45:1148–1156. 1999.
15	Lyon E, Millson A, Lowery MC, Woods R and Wittwer CT: Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem. 47:844–851. 2001.
16	Riehle U, Mader A, Brandstetter T, Rühe J, zur Hausen A and Stickeler E: Nucleic acid sequence-based amplification in formalin-fixed and paraffin-embedded breast-cancer tissues. J Clin Pathol. 63:1071–1076. 2010.